ROTH Capital Partners Acts as Lead Placement Agent for
Biocept, Inc. (NASDAQ: BIOC) in its $9.3 Million Registered Direct

For more information please contact:

Investment Banking
Ted Roth
President
(949) 720-5753
troth@roth.com


Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703

agurewitz@roth.com

 

Nazan Akdeniz
Senior Vice President
(949) 720-5740

nakdeniz@roth.com

 

Lou Ellis
Senior Vice President
(949) 720-5739

lellis@roth.com

Transaction Information

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, has completed a sale of 4,320,000 shares of common stock at a price of $2.15 per share and warrants to purchase up to 2,160,000 shares of common stock with an exercise price of $2.50 per share. The warrants will be exercisable six months following the closing date and will expire five years from the date they become exercisable. The gross proceeds of the offering are expected to be approximately $9.3 million. Biocept, Inc. intends to use the proceeds for working capital and general corporate purposes.

  

ROTH Capital Partners acted as lead placement agent in the offering.

 

About Biocept, Inc.
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com. (Source: Company Press Release | 3/28/17)

 

About ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S.  For more information on ROTH, please visit www.roth.com.

About ROTH Investment Banking Venture Finance Institutional Sales & Trading
Research Corporate Services Marketing & Conferences Press Room

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2017.